Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!
pixel
Richard H. Scheller Insider Alerts

Get notified the next time Richard H. Scheller buys or sells BridgeBio Pharma stock. Enter your email address below to get our daily insider buying and selling report.

Richard H. Scheller Insider Information

Insider of BridgeBio Pharma


Richard H. Scheller, Ph.D. has served as a member of our Board of Directors since January 2018 and as our Chairman of Research & Development effective as of January 2019. Dr. Scheller served as the Chief Science Officer and Head of Therapeutics at 23andMe, a personal genetics company, from 2015 to April 2019. Previously, Dr. Scheller was the Executive Vice President of Research and Early Development and a member of the Executive Committee at Genentech, Inc., a biotechnology corporation, from February 2001 to December 2014. From January 2009 to December 2014, Dr. Scheller was also a member of the Enlarged Executive Committee at Hoffmann-La Roche Ltd, a pharmaceutical company. Dr. Scheller currently serves as a member of the board of directors ORIC Pharmaceuticals, Inc., a biopharmaceutical company, since February 2015, Alector, Inc., a biopharmaceutical company (Nasdaq: ALEC), since October 2018, DiCE Molecules, a biopharmaceutical company, and Maze Therapeutics, a biopharmaceutical company, since July 2019. Dr. Scheller holds a B.Sc. in Biochemistry from the University of Wisconsin-Madison and a Ph.D. in Chemistry from the California Institute of Technology. He completed his post-doctorate in Molecular Neurobiology at Columbia University and was also a post-doctorate fellow at California Institute of Technology. Dr. Scheller’s qualifications to serve on our Board of Directors include his scientific background and his senior management experience in the pharmaceutical industry.

What is Richard H. Scheller's net worth?

The estimated net worth of Richard H. Scheller is at least $2.29 million as of May 13th, 2021. Dr. Scheller owns 49,200 shares of BridgeBio Pharma stock worth more than $2,291,244 as of October 22nd. This net worth evaluation does not reflect any other assets that Dr. Scheller may own. Learn More.

How do I contact Richard H. Scheller?

The corporate mailing address for Dr. Scheller and other BridgeBio Pharma executives is 421 Kipling Street, Palo Alto CA, 94301. BridgeBio Pharma can also be reached via phone at (650) 391-9740.

Has Richard H. Scheller been buying or selling shares of BridgeBio Pharma?

Richard H. Scheller has not been actively trading shares of BridgeBio Pharma over the course of the past ninety days. Most recently, Richard H. Scheller sold 13,777 shares of the business's stock in a transaction on Wednesday, August 4th. The shares were sold at an average price of $53.23, for a transaction totalling $733,349.71.

Are insiders buying or selling shares of BridgeBio Pharma?

In the last year, BridgeBio Pharma insiders bought shares 2 times. They purchased a total of 24,000 shares worth mmore than $1,500,000.00. In the last year, insiders at the sold shares 9 times. They sold a total of 3,576,920 shares worth mmore than $216,146,412.69. The most recent insider tranaction occured on August, 04th when Richard H Scheller Insider bought 13,777 shares worth more than $733,349.71. Insiders at BridgeBio Pharma own 28.3 % of the company.

Information on this page was last updated on 8/4/2021.

Richard H. Scheller Insider Trading History at BridgeBio Pharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/4/2021Sell13,777$53.23$733,349.71View SEC Filing Icon  
12/21/2020Sell60,401$65.32$3,945,393.3291,333View SEC Filing Icon  
See Full Table

Richard H. Scheller Buying and Selling Activity at BridgeBio Pharma

This chart shows Richard H Scheller's buying and selling at BridgeBio Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BridgeBio Pharma Company Overview

BridgeBio Pharma logo
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.
Read More

Today's Range

Now: $46.57
Low: $45.43
High: $46.66

50 Day Range

MA: $49.18
Low: $44.11
High: $52.23

2 Week Range

Now: $46.57
Low: $37.29
High: $73.50

Volume

23,277 shs

Average Volume

835,494 shs

Market Capitalization

$6.97 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.79
Worried About Inflation? Listen To This Top Analyst
While the value of the US Dollar sinks faster than the titanic. There's a booming industry that's about to make investors very happy. It has already skyrocketed over 160% the past few years. And it could make a great hedge against inflation.
Click Here If You're Worried About Inflation